Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' RIXE O' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 50 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Faivre, S; Raymond, E; Boige, V; Gatineau, M; Buthaut, X; Rixe, O; Bernareggi, A; Camboni, G; Armand, JP
      A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies

      CLINICAL CANCER RESEARCH
    2. Rixe, O
      Concomitant radiochemotherapy for non-small-cell lung cancer: towards an ideal strategy

      REVUE DES MALADIES RESPIRATOIRES
    3. Becouarn, Y; Gamelin, E; Coudert, B; Negrier, S; Pierga, JY; Raoul, JL; Provencal, J; Rixe, O; Krisch, C; Germa, C; Bekradda, M; Mignard, D; Mousseau, M
      Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients

      JOURNAL OF CLINICAL ONCOLOGY
    4. Kissel, A; Rixe, O; Methlin, A; Nabet, M; Tranquart, F; Rubini, B; Jafaar, S; Gaucher, H
      Quantification of hepatic arterial and portal venous flow using US contrast agents for early detection of liver metastases from colon carcinoma

      JOURNAL DE RADIOLOGIE
    5. Zelek, L; Barthier, S; Riofrio, M; Fizazi, K; Rixe, O; Delord, JP; Le Cesne, A; Spielmann, M
      Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma

      CANCER
    6. Vandier, D; Rixe, O; Besnard, F; Kim, M; Rikiyama, T; Goldsmith, M; Brenner, M; Gouyette, A; Cowan, KH
      Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter

      CANCER GENE THERAPY
    7. Delord, JP; Raymond, E; Chaouche, M; Ruffie, P; Ducreux, M; Faivre, S; Boige, V; Le Chevalier, T; Rixe, O; Baudin, E; Pautier, P; Rodier, JM; Chouaki, N; Escudier, B; Kayitalire, L; Armand, JP
      A dose-finding study of gemcitabine and vinorelbine in advanced previouslytreated malignancies

      ANNALS OF ONCOLOGY
    8. Boige, V; Raymond, E; Faivre, S; Gatineau, M; Meely, K; Mekhaldi, S; Pautier, P; Ducreux, M; Rixe, O; Armand, JP
      Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer

      JOURNAL OF CLINICAL ONCOLOGY
    9. Rixe, O
      Platinum compounds: mechanisms of action, mechanisms of cellular resistance in human cancers, interactions with ionising radiations, application to carboplatin

      BULLETIN DU CANCER
    10. Vandier, D; Calvez, V; Massade, L; Gouyette, A; Mickley, L; Fojo, T; Rixe, O
      Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: a specific gene therapy strategy

      JOURNAL OF THE NATIONAL CANCER INSTITUTE
    11. Spielmann, M; Llombart, A; Zelek, L; Sverdlin, R; Rixe, O; Le Cesne, A
      Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer

      ANNALS OF ONCOLOGY
    12. FIZAZI K; CULINE S; DROZ JP; TERRIERLACOMBE MJ; THEODORE C; WIBAULT P; RIXE O; RUFFIE P; LECHEVALIER T
      INITIAL MANAGEMENT OF PRIMARY MEDIASTINAL SEMINOMA - RADIOTHERAPY OR CISPLATIN-BASED CHEMOTHERAPY

      European journal of cancer
    13. FAIVRE S; RAYMOND E; RIXE O; GOLDWASSER F; MANGOLD GL; VONHOFF DD; JUNIEWICZ P; CVITKOVIC E
      PRECLINICAL SYNERGY OF OXALIPLATIN IN COMBINATION WITH OTHER ANTITUMOR AGENTS

      Annals of oncology
    14. FAIVRE S; RAYMOND E; RIXE O; GOLDWASSER F; MANGOLD GL; VONHOFF DD; JUNIEWICZ P; CVITKOVIC E
      IN-VITRO AND IN-VIVO RATIONATE FOR OXALIPLATIN IN COMBINATION WITH OTHER ANTITUMOR AGENTS

      Annals of oncology
    15. RIXE O; GATINEAU M; BATOUCHE M; RAYMOND E; DOMENGE C; JANOT F; SCHWAAB G; LUBOINSKI B; ARMAND JP
      SEQUENTIAL NEOADJUVANT CHEMOTHERAPY (SC) FOR HEAD AND NECK SQUAMOUS-CELL CARCINOMA (HNSCC)

      Annals of oncology
    16. MATHURIN P; RIXE O; CARBONELL N; BERNARD B; CLUZEL P; BELLIN MF; KHAYAT D; OPOLON P; POYNARD T
      REVIEW ARTICLE - OVERVIEW OF MEDICAL TREATMENTS IN UNRESECTABLE HEPATOCELLULAR-CARCINOMA - AN IMPOSSIBLE METAANALYSIS

      Alimentary pharmacology & therapeutics
    17. VANDIER D; RIXE O; BRENNER M; GOUYETTE A; BESNARD F
      SELECTIVE KILLING OF GLIOMA CELL-LINES USING AN ASTROCYTE-SPECIFIC EXPRESSION OF THE HERPES-SIMPLEX VIRUS THYMIDINE KINASE GENE

      Cancer research
    18. FIZAZI K; COJEAN I; PIGNON JP; RIXE O; GATINEAU M; HADEF S; ARRIAGADA R; BALDEYROU P; COMOY E; LECHEVALIER T
      NORMAL SERUM NEURON-SPECIFIC ENOLASE (NSE) VALUE AFTER THE FIRST CYCLE OF CHEMOTHERAPY - AN EARLY PREDICTOR OF COMPLETE RESPONSE AND SURVIVAL IN PATIENTS WITH SMALL-CELL LUNG-CARCINOMA

      Cancer
    19. GATINEAU M; RIXE O; REY A; TRANDAFIR L; LECHEVALIER T
      PHASE I II STUDY OF THE ADDITION OF TIRAPAZAMINE (TIRA) TO CISPLATINE(CDDP)/NAVELBINE (NVB) IN PATIENTS WITH INOPERABLE NON-SMALL-CELL LUNG-CANCER (NSCLC)/

      European journal of cancer
    20. ANTOINE EC; RIXE O; AUCLERC G; WEIL M; KHAYAT D
      DOCETAXEL - A REVIEW OF ITS ROLE IN BREAST-CANCER-TREATMENT

      American journal of clinical oncology
    21. RIXE O; COEFFIC D; ORCEL B; MAITRE B; BOREL C; BENHAMMOUDA A; PETIT T; KHAYAT D; DERENNE JP
      A PHASE-II STUDY OF CISPLATIN, 5-FLUOROURACIL, LEUCOVORIN, AND ETOPOSIDE IN ADVANCED NON-SMALL-CELL LUNG-CANCER

      American journal of clinical oncology
    22. COEFFIC D; BENHAMMOUDA A; ANTOINE EC; RIXE O; PARAISO D; AUCLERC G; RENODY N; MULARONI E; SOUBRANE C; WEIL M; MORTIER N; KHAYAT D
      PRELIMINARY-RESULTS OF A PHASE I II STUDY OF PACLITAXEL, CISPLATIN, AND CYCLOPHOSPHAMIDE IN ADVANCED OVARIAN-CARCINOMA/

      Seminars in oncology
    23. SORIA JC; RIXE O
      TELOMERES, TELOMERASE AND CANCER

      Bulletin du cancer
    24. FIZAZI K; FARHAT F; THEODORE C; RIXE O; LECESNE A; COMOY E; LECHEVALIER T
      CA125 AND NEURON-SPECIFIC ENOLASE (NSE) AS TUMOR-MARKERS FOR INTRAABDOMINAL DESMOPLASTIC SMALL ROUND-CELL TUMORS

      British Journal of Cancer
    25. MOUAWAD R; BENHAMMOUDA A; RIXE O; ANTOINE EC; BOREL C; WEIL M; KHAYAT D; SOUBRANE C
      ENDOGENOUS INTERLEUKIN-6 LEVELS IN PATIENTS WITH METASTATIC MALIGNANT-MELANOMA - CORRELATION WITH TUMOR BURDEN

      Clinical cancer research
    26. CALVEZ V; RIXE O; WANG P; MOUAWAD R; SOUBRANE C; GHOUMARI A; VEROLA O; KHAYAT D; COLBEREGARAPIN F
      VIRUS-FREE TRANSFER OF THE HERPES-SIMPLEX VIRUS THYMIDINE KINASE GENEFOLLOWED BY GANCICLOVIR TREATMENT INDUCES TUMOR-CELL DEATH

      Clinical cancer research
    27. GHOUMARI AM; RIXE O; YAROVOI SV; ZERROUQI A; MOUAWAD R; POYNARD T; OPOLON P; KHAYAT D; SOUBRANE C
      GENE-TRANSFER IN HEPATOCARCINOMA CELL-LINES - IN-VITRO OPTIMIZATION OF A VIRUS-FREE SYSTEM

      Gene therapy
    28. YAROVOI SV; MOUAWAD R; COLBEREGARAPIN F; SOUBRANE C; KHAYAT D; RIXE O
      IN-VITRO SENSITIZATION, OF THE B16 MURINE MELANOMA-CELLS TO GANCICLOVIR BY DIFFERENT RNA AND PLASMID DNA CONSTRUCTIONS ENCODING HSVTK

      Gene therapy
    29. SOUBRANE C; MOUAWAD R; RIXE O; CALVEZ V; GHOUMARI A; VEROLA O; WEIL M; KHAYAT D
      DIRECT GENE-TRANSFER OF A PLASMID CARRYING THE HERPES-SIMPLEX VIRUS-THYMIDINE KINASE GENE (HSV TK) IN TRANSPLANTED MURINE MELANOMA - IN-VIVO STUDY

      European journal of cancer
    30. ZERROUQI A; RIXE O; GHOUMARI AM; YAROVOI SV; MOUAWAD R; KHAYAT D; SOUBRANE C
      LIPOSOMAL DELIVERY OF THE HERPES-SIMPLEX VIRUS THYMIDINE KINASE GENE IN GLIOMA - IMPROVEMENT OF CELL SENSITIZATION TO GANCICLOVIR

      Cancer gene therapy
    31. MOUAWAD R; SOUBRANE C; BOREL C; RIXE O; BENHAMMOUDA A; WEIL M; KHAYAT D
      SERUM INTERLEUKIN-6 LEVELS IN METASTATIC MALIGNANT-MELANOMA (MMM) PATIENTS TREATED BY BIOCHEMOTHERAPY - CORRELATION WITH TUMOR BURDEN AND CLINICAL-RESPONSE

      The FASEB journal
    32. BENARD J; RIXE O
      ANTICANCER DRUG-RESISTANCE

      La Presse medicale
    33. COEFFIC D; BENHAMMOUDA A; ANTOINE EC; RIXE O; PARAISO D; AUCLERC G; NIZRI D; RENODY N; GRAPIN JP; MULARONI E; RATTINI E; SOUBRANE C; WEIL M; MORTIER N; KHAYAT D
      PHASE I II STUDY OF PACLITAXEL, CISPLATIN, AND CYCLOPHOSPHAMIDE IN ADVANCED OVARIAN-CARCINOMA - PRELIMINARY-RESULTS/

      Seminars in oncology
    34. PETIT T; BOREL C; RIXE O; AVRIL MF; MONNIER A; GIROUX B; WEIL M; KHAYAT D
      COMPLETE REMISSION 7 YEARS AFTER TREATMENT FOR METASTATIC MALIGNANT-MELANOMA

      Cancer
    35. RIXE O; ORTUZAR W; ALVAREZ M; PARKER R; REED E; PAULL K; FOJO T
      OXALIPLATIN, TETRAPLATIN, CISPLATIN, AND CARBOPLATIN - SPECTRUM OF ACTIVITY IN DRUG-RESISTANT CELL-LINES AND IN THE CELL-LINES OF THE NATIONAL-CANCER-INSTITUTE ANTICANCER DRUG SCREEN PANEL

      Biochemical pharmacology
    36. RIXE O; BOREL C; PARAISO D; BENHAMMOUDA A; PETIT T; ANTOINE E; BIZZARI JP; AUCLERC G; SOUBRANE C; WELL M; GIROUX B; BANZET P; KHAYAT D
      FOTEMUSTINE, DACARBAZINE, VINDESINE COMBINATION CHEMOTHERAPY IN ADVANCED MALIGNANT-MELANOMA - A PHASE-II STUDY OF 43 PATIENTS

      Melanoma research
    37. RIXE O; BENHAMMOUDA A; FARABOS C; BOREL C; PETIT T; AUCLERC G; COEFFIC D; BASTIAN G; GROSSIN F; PARAISO D; GRAPIN JP; NIZRI D; WEIL M; BISMUTH H; MAHJOUBI M; KHAYAT D
      A PHASE-I STUDY OF CONCOMITANT CPT-11 (C) AND 5FU (F) COMBINATION - PRELIMINARY-RESULTS

      European journal of cancer
    38. MOUAWAD R; CALVEZ V; RIXE O; GHOUMARI A; VEROLA O; GARAPIN F; KHAYAT D; SOUBRANE CI
      REGRESSION OF TRANSPLANTED MURINE MELANOMA AFTER VIRUS-FREE TRANSFER OF A SUICIDE GENE

      The FASEB journal
    39. ANTOINE EC; RIXE O; VUILLEMIN E; BENHAMMOUDA A; BOREL C; GHIRONZI GC; MULARONI E; FRANKS C; AUCLERC G; SOUBRANE C; BANZET P; WEIL M; KHAYAT D
      A PHASE-II STUDY OF TAMOXIFEN COMBINED WITH CISPLATIN-INTERLEUKIN-2 AND ALPHA-INTERFERON IN METASTATIC MELANOMA

      American journal of clinical oncology
    40. MATHURIN P; RIXE O; CARBONEL N; CLUZEL P; BERNARD B; KHAYAT D; OPOLON P; POYNARD T
      METAANALYSIS OF MEDICAL TREATMENTS IN HEPATOCELLULAR-CARCINOMA

      Hepatology
    41. WEIL M; BOREL C; RIXE O; ANTOINE E; AUCLERCI G; BANZET P; KHAYAT D
      ADJUVANT TREATMENT OF EXCISED MELANOMA IN STAGE-I

      Annales de dermatologie et de venereologie
    42. PETIT T; NIZRI D; COEFFIC D; RIXE O; KHAYAT D
      SUBCLAVICULAR SKIN METASTASIS OF CERVICAL -CANCER

      Annales de medecine interne
    43. BUTHIAU D; RIXE O; NIZRI D; PIETTE JC; KHAYAT D
      BREAST-CANCER - FOLLOW-UP BY MRI

      Bulletin de l'Academie nationale de medecine
    44. AUCLERC G; RIXE O; WEIL M; KHAYAT D
      SERUM TUMOR-MARKERS

      Contraception fertilite sexualite
    45. MOUAWAD R; ICHEN M; KHAVAT D; RIXE O; BENHAMMOUDA A; WEIL M; SOUBRANE O
      ROLE OF CELLULAR INTERLEUKIN-2 RECEPTORS (IL2R) IN CELL STIMULATION AFTER CHEMOIMMUNOTHERAPY (CI) IN METASTATIC MALIGNANT-MELANOMA (MMM) PATIENTS (PTS)

      The FASEB journal
    46. RIXE O; BENHAMMOUDA A; ANTOINE E; PETIT T; TOURANI JM; BOREL C; FRANKS C; KALIF B; MOUSSEAU M; THOMAS A; BENSFIA S; NIZRI D; SOUBRANE C; HERRERA A; BIZZARI JP; AUCLERC G; WEIL M; BANZET P; KHAYAT D
      CHEMOIMMUNOTHERAPY OF METASTATIC MELANOMA - CISPLATIN, INTERLEUKIN-2 AND IFN-ALPHA IN 91 PATIENTS

      Pathologie et biologie
    47. MOUAWAD R; ICHEN M; RIXE O; BENHAMMOUDA A; VUILLEMIN E; WEIL M; KHAYAT D; SOUBRANE C
      STUDY OF IL-2 RECEPTOR EXPRESSION AFTER CHEMOIMMUNOTHERAPY IN PATIENTS TREATED FOR METASTATIC MALIGNANT-MELANOMA

      Clinical and experimental immunology
    48. SOUBRANE C; MOUAWAD R; ICHEN M; BENHAMMOUDA A; RIXE O; WEIL M; KHAYAT D
      IL2 RECEPTOR EXPRESSION IN METASTATIC MAL IGNANT-MELANOMA PATIENTS TREATED BY BIOCHEMOTHERAPY

      Bulletin du cancer
    49. KHAYAT D; ANTOINE E; RIXE O; TOURANI JM; VUILLEMIN E; BOREL C; BENHAMMOUDA A; THILL L; FRANKS C; AUCLERC G; WEIL M; SOUBRANE C; BANZET P
      CHEMOIMMUNOTHERAPY OF METASTATIC MALIGNANT-MELANOMA THE SALPETRIERE HOSPITAL (SOMPS) EXPERIENCE

      European journal of cancer
    50. KHAYAT D; BOREL C; TOURANI JM; BENHAMMOUDA A; ANTOINE E; RIXE O; VUILLEMIN E; BAZEX PA; THILL L; FRANKS R; AUCLERC G; SOUBRANE C; BANZET P; WEIL M
      SEQUENTIAL CHEMOIMMUNOTHERAPY WITH CISPLATIN, INTERLEUKIN-2, AND INTERFERON ALFA-2A FOR METASTATIC MELANOMA

      Journal of clinical oncology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/01/21 alle ore 20:11:37